INSMED Inc
INSM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$93.39
KIRA · Stoqly’s AI analyst, in plain words
- INSMED Inc had $606M of revenue in fiscal 2025, up 66.7% on the year before. Over five years, revenue changed +29.8% a year on average.
- Its operating margin was −205.6%, up 35.9 pts: of every 100 in sales, about −206 is left after running the business.
- INSMED Inc lost $1.3B in fiscal 2025.
- Free cash flow was −$968M in fiscal 2025, −159.6% of revenue.
- INSMED Inc has $859M more cash than debt.
Market cap
$20.3B
P/E
—
Revenue
$606M
Net income
−$1.3B
Free cash flow
−$968M
Operating margin
−205.6%
INSMED Inc in 30 seconds · fiscal 2025
Are sales growing?
+66.7%
Yes. Sales grew 66.7% last year.
Does it make a profit?
−210.5%
No. It lost money last year.
Does profit turn into cash?
−159.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What INSMED Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- INSMED Inc
- CIK
- 0001104506
INSMED Inc · INSM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $188M | $245M | $305M | $364M | $606M |
| Revenue growth | 14.6% | 30.2% | 24.4% | 19.2% | 66.7% |
| Gross margin | 76.6% | 77.5% | 78.5% | 76.4% | 79.7% |
| Operating margin | −199.0% | −186.4% | −232.5% | −241.5% | −205.6% |
| Net income | −$435M | −$482M | −$750M | −$914M | −$1.3B |
| Net margin | −230.6% | −196.3% | −245.6% | −251.2% | −210.5% |
| Diluted EPS | −$3.88 | −$3.91 | −$5.34 | −$5.57 | −$6.42 |
| Cash | |||||
| Cash from operations | −$363M | −$400M | −$536M | −$684M | −$935M |
| Capital expenditure | $7.3M | $9.9M | $13.3M | $21.9M | $32.6M |
| Free cash flow | −$371M | −$410M | −$550M | −$706M | −$968M |
| FCF margin | −196.6% | −167.2% | −180.1% | −194.1% | −159.6% |
| Share count change | 14.9% | 9.7% | 14.1% | 16.8% | 21.3% |
| Debt and strength | |||||
| Cash and short-term investments | $717M | $1.1B | $780M | $1.4B | $1.4B |
| Debt incl. finance leases | $815M | $1.2B | $1.2B | $1.1B | $571M |
| Shareholders' equity | $410M | $88.0M | −$332M | $285M | $739M |
| Current ratio | 6.2x | 6.7x | 4.1x | 5.5x | 3.8x |
| Interest coverage | −9.3x | −17.3x | −8.7x | −10.3x | −14.9x |
| Returns and quality | |||||
| Return on capital | −60.0% | −385.0% | −860.3% | — | — |
| Return on equity | −126.7% | −193.2% | — | — | −249.3% |
| Return on tangible equity | −216.7% | — | — | −1,008.4% | −252.7% |
| Piotroski F-score | 4 | 4 | 3 | 4 | 4 |
| Altman Z'' | −3.7 | −2.8 | −8.8 | −5.5 | −7.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$167M
10 insiders
Of sales under plans
56%
$94.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
INSMED Inc · INSM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $93.39 a share, the company is worth $20.3B.
Source: SEC EDGAR XBRL filings (CIK 0001104506). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.